Stem cell combo shows promise for deadly transplant complication
Disease control
Not yet recruiting
This Phase 3 trial tests whether adding a stem cell therapy called remestemcel-L to the drug ruxolitinib can help adults with severe, steroid-resistant graft-versus-host disease (GVHD) after a bone marrow transplant. GVHD occurs when donor immune cells attack the patient's body. …
Phase: PHASE3 • Sponsor: Mesoblast, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC